Ricevi le ultime notizie sulle azioni Vor Biopharma con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di VOR

Ultime notizie per

VOR BIOPHARMA INC

Vor Biopharma

Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

ADIL

BDMD

BLNE

CBIO

GCTK

KTOS

MKDW

MLKN

ORIS

PRTG

RVPH

SAFX

ZVSA

Worthington sorprende con utili superiori alle attese: +15,7% in pre-market. Balzi anche per VOR, ADIL e ALT. Ecco i titoli top di oggi.

Azioni di Worthington Steel salgono di oltre il 15%; Ecco 20 azioni in movimento nel pre-market USA

Vor Biopharma Inc

Virgin Orbit Holdings Inc

Virgin Orbit Holdings Inc Warrants (29/12/2026)

Vortex Brands Co

Vornado Realty Trust

Vornado Realty Trust 5.25% Series M Cumulative Redeemable Preferred Shares of Beneficial Interest, liquidation preference $25.00 per share, no par value per share

Vornado Realty Trust 4.45% Series O Cumulative Redeemable Preferred Shares, Liquidation Preference $25.00 Per Share

Vornado Realty Trust 5.25% Series N Cumulative Redeemable Preferred Shares of Beneficial Interest, liquidation preference $25.00 per share

VORTEX ENERGY CORP by Vortex Energy Corp.

Vortex Energy Corp

VORNADO RLTY TR 6.50 A PR by Vornado Realty Trust

Vortex Energy Corp Ordinary Shares

Vortex Metals Inc

News

Press Releases

Vor Bio to Participate in Upcoming Investor Conferences

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy

PureTech Health plc – Half-Year Report

Health Care

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM

Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting

Management

Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer

Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren's Disease Clinical Study at ACR Convergence 2025

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRTC

REGMY

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Cabaletta Bio

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Crescent Biopharma

Fennec Pharmaceuticals Inc. - Common Stock

Fennec Pharmaceuticals

Foghorn Therapeutics

Heron Therapeutics

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Invivyd

Jade Biosciences

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Puma Biotechnology

ProQR Therapeutics N.V. - Ordinary Shares

ProQR Therapeutics

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Tenaya Therapeutics

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

Exagen

Zura Bio Limited - Class A Ordinary shares

Comments

Vor Biopharma Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO